waypoint wealth counsel Sells 163 Shares of Eli Lilly and Company $LLY

waypoint wealth counsel reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 20.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 629 shares of the company’s stock after selling 163 shares during the quarter. waypoint wealth counsel’s holdings in Eli Lilly and Company were worth $490,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. WestEnd Advisors LLC raised its holdings in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC raised its stake in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on LLY shares. HSBC increased their price target on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Berenberg Bank reissued a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $833.08 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The firm has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a P/E/G ratio of 1.16 and a beta of 0.47. The firm’s 50-day simple moving average is $742.42 and its 200 day simple moving average is $765.94. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm earned $3.92 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.